DCCBs May Harm Kidneys in Diabetics | Science News

New research is sounding the alarm on a widely used blood pressure drug, dihydropyridine calcium-channel blockers (DCCBs), especially for people with type 2 diabetes and kidney issues. A large study of over 31,000 patients found those taking DCCBs alongside kidney-protective drugs had a 33% higher risk of serious kidney decline. While these drugs are often prescribed as a second-line option, the findings suggest they may not be safe—even when paired with newer treatments like RAS inhibitors and SGLT2 inhibitors. The suspected mechanism involves DCCBs unevenly relaxing kidney blood vessels, increasing internal pressure and worsening damage. Though the study can’t prove causation, the association is strong enough to prompt urgent calls for more research and potentially rethink treatment guidelines for millions at risk. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/32081a3edac6617c